Особенности фармакокинетического взаимодействия лекарственных средств на уровне СУР 2Д6 и СУР 3А4
Диссертация
Основные результаты доложены и обсуждены на научно-практической конференции кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета Московской Медицинской Академии им. И. М. Сеченова совместно с сотрудниками ГКБ № 23 им. «Медсантруд» г. Москвы и сектора фармакокинетики Проблемной Лаборатории лекарственных средств РАМН и Института клинической фармакологии ФГУ НЦ… Читать ещё >
Список литературы
- Гланц С. Медико-биологическая статистика. Пер. с англ. — М., Практика: 1999. — 443 с.
- Катцунг Г. Бертрам. Базисная и клиническая фармакология. С-Пб. -Невский Диалект. — 1998. — Т.1. — С. 73−86.
- Кукес В.Г. Клиническая фармакология. М. — Медицина. — 1999. — С. 14−19.
- Кучумов Р.С. Значение генотипирования полиморфных «медленных» аллелей цитохрома Р- 450 2D6 для индивидуализированной оценки фармакокинетики амитриптиллина в московской популяции.//Автореф. .канд.мед.наук.-Москва-2002.
- Лепахин В.К., Белоусов Ю. Б., Моисеев B.C. Клиническая фармакология с международной номенклатурой лекарств. — М.-Издательство Университета дружбы народов.- 1988.- С. 45−51.
- Лильин Е.Т., Богомазов Е. А., Гофман-Кадошников П.Б. Генетика для врача. М. — Медицина. — 1990- С. 176−187.
- Лоуренс Д.Р., Беннит П. Н. Клиническая фармакология. М. — Медицина. — 1993.- Т.1.- С. 208−215.
- Метаболизм лекарственных препаратов. Под редакцией акад. РАМН, проф. Кукеса В. Г., член-корр. РАМН, проф. Фисенко В.П.- М. -Палея-М. 2001.- С. 5−28, 52−64, 91−96.
- Сидоренко Б.А., Преображенский Д. В., Пересыпко М. К. Новые подходы к классификации и лечению артериальной гипертензии. Рекомендации Всемирной организации здравоохранения и Международного общества по гипертензии 1999r.//Consilium Medicum-2000-T.3- № 2.
- И. Смолярчук Е. А. Значение функциональной активности CYP ЗА4 в метаболизме блокаторов медленных кальциевыхканалов.//Автореф. .канд.мед.наук.-Москва-2002.
- Щербаков B.M., Тихонов A.B. Изоферменты цитохрома Р-450 печени человека. М. АО «Биохимические технологии».-1995.- С. 3−10, 38−53.
- Alberts A.W. Lovastatin and simvastatin inhibitors of HMG CoA reductase and cholesterol biosynthesis // Cardiology. 1990- 77 supl 4: 1421.
- Andreeva M, Niedmann PD, Schutz E, Wieland E, Armstrong VW, Oellerich M. MEGX determination by use of HPLC with fluorescence determination Technical Brief.// Clin.Chem.- 1997- 43: 1081−3.
- Bailey DG, Arnold M, Spence JD. Grapefruit juice-drug interactions.// Br J Clin Pharmacol.-1998- 46: 101−110.
- Baker L. University of Michigan Ann Arbor. //Personal communication.-1999- 32−45.
- Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Iohansson I et al. Molecular basis for rational megaprescripting in ultrarapid hydroxylators of debrisoquin.// Lancet. 1993: 341, 363.
- Board P, Coggan M, Johnston P, Ross V, Suzuki T, Webb G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families.//Pharm. Therap.- 1990- 48: 357−369.
- Brater C. et al. General principles of drug interactions. // J Clin Pharmacol.-2001−5:34−37.
- Buehler В A, Delimont D, van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. // New Eng. J. Med.-1990- 322: 15 671 571.
- Burchell B, McGurc K, Brierley CH, Clarke DJ. UDP-glucouronosiltransferases. // Comprehensiv toxicology -1996- 401−435.
- Cappiello M, Franchi M, Giuliani L and Pacifici GM. Distribution of 2-naphthol sulphotransferase and its endogenous substrate adenosine 3'-phosphate 5-phosphosurphate in human tissues. // Eur J Clin Pharmacol. -1989−37:317−320.
- Cappiello M, Giuliani L and Pacifici GM. Distribution of UDP-glucuronosyltransferase and its endogenous substrate uridine 5'-diphosphoglucuronic acid in human tissues. //Eur J Clin Pharmacol. 1991- 41:345−350.
- Chang GW, Kam PCA. The physiological and p harmacological roles о f cytochrome P450 isoenzymes. // Anaesthesia 1999,54:42−50 .
- Chen C., Cook L.S., Li X.Y., Hallagan S., Madeleine M.M., Daling J.R., Weiss N.S.// CYP2D6 genotype and the incidence of anal and vulvar cancer.// Cancer Epidemiol. Biomarkers Prev.- 1999, Vol. 8(4 Pt 1) P.317−321-.
- Cupp MJ, Tracy TS. Cytochrome P450: New Nomenclature and Clinical Implications. // Amer Fam Phys. 1998,57(1): 107−116 .
- Curtis E. Haas, Pharm.D., David C. Kaufman, M.D., and Robert C. DiCenzo, Pharm.D. Effects of Metronidazole on Hepatic CYP3A4 Activity.//Pharmacotherapy-2001- 21 (10): 1192−1195.
- Dubey RK, Singh J. Localization and characterization of drug-metabolizingenzymes along the villus-crypt surface of the rat small intestine II. Conjugates. //Biochem Pharmacol. 1998- 37: 177−184.
- Dukes. M. Meylers side effects of drug. -Tokyo.- 1996.C.135−154,248,567.
- Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. // Biochem.Pharmacol. 1988- 37: 93−96.
- Eichelbaum M, Echizen H. Clinical pharmacology of calcium antagonists: a critical review.// J.Cardiovasc.Pharmacol. -1984- 6: S963-S967.
- Engelke CE, Meinl W, Boeing H, Glatt H. Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. // Pharmacogenetics 2000 Mar- 10 (2): 163−169.
- Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. // Brit. Med. J. 1960- 2: 485−491.
- Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. Association of CYP3A4 genotype with treatment-related leukemia.// Proc Natl Acad Sci USA. -1998 27- 95.
- Finta C, Zaphiropoulos PG. The human cytochrome P450 ЗА locus. Gene evolution by capture of downstream exons. // Gene 2000 — 260 (1−2): 1323.
- Flemming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N-hydroxylation of dapson by cytochrome P4503A4 .// Pharmacologist-1990- 32: 140.
- Fontana RJ., Lown KS., Paine MF., Fortlage L. et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. // Gastroenterology 1999- 117: 89−98.
- Fromm MF, Busse D, Kroemer HK and Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. // Hepatology -1996- 24: 796−801.
- Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome Р-450 3a (CYP3A4) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. // Drug Metab. Dispos.1999,27: 180−187.
- Glatt H, Engelke СЕ, Pabel U, Teubner W, Jones AL, Coughtrie MW, Andrae U, Falany CN, Meinl W. Sulfotransferases: genetics and role in toxicology. // Toxicol Lett 2000 — 112−113: 341−348.
- Gregg C.R. Drug interactions and anti-infective therapies. //The American Journal of Medicine.- 1999- 2: 227−237.
- Guengerich FP. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. // Toxicol Lett -1994- 70: 133 138.
- Guengerich F. P. С ytochrome P-450 3 A4: Regulation and Role in Drug Metabolism. // Annual Reviews Pharmacol. Toxicol.- 1999- 39: 1−17.
- Guengerich FP. Mechanism based inactivation of humal liver microsomal cytochrome P-450 IIIA4 by gestoden. // Chem.Res.Toxicol. -1990- 3: 363 371.
- Guengerich FP, Brian WR, Iwasaki M, Saria MA, Baarhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. // J Med Chem. 1991- 34: 1838−1844.
- Harris CC. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. // Carcinogenesis. -1989- 10: 1563−1566.
- Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. // Clin Pharmacol Ther. -1992- 52: 453−457.
- Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquin by allele-specific PCR amplification. // Lancet. 1990- 336: 529−532.
- Hirth J, Watkins P B, S trawderman M, S chott A, В runo R, В aker L. The effect of an individual’s cytochrome CYP3A4 activity on doxetaxelclearance.// Clin. Cancer Res. -2000,6: 1255−1258.
- Honig P.K., Woosley R.L., Zamani K. et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. // Clin Pharmacol Ther. 1992−52:231−238.
- Imaoka S, Enomoto K, Oda Y, Asada A, Fujimori M, Shimada T. Lidocaine metabolism by human cytochrome P450's purified from hepatic microsomes: comparison with rat hepatic cytochrome P450's. // J Pharmacol Ther. 1990- 255: 1385−1391.
- Ingelman-Sundberg M. et al. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment .// Trends in Pharm Sci Aug. 1999, 342−349.
- Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome P450IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver micijsjmes. // Biochem Pharmacol. -1991- 41: 1911−1919.
- Jamis-Dow С A, P earl M L, W atkins P В, В lake D S, К lecker RW, С ollins JM. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. // Am J Clin Oncol. 1997- 20: 592−599.
- Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identificacion of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IAI gene.// FEBS Lett. -1990- 263: 131−133.
- Keffe M. Liver transplantation. // Current opinion in gastroenterology. -1996- 12:290.
- Keith G. Tolman. Hepatotoxicity of non-narcotic analgesics.// The American Journal of Medicine. 1998- IB: 13S-19S.
- Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. // Brit. J. Clin. Pharm.-1999,48:716−727.
- Kinirons MT, O’Shea D, Downing ТЕ, Fitzwilliam AT, Joellenbeck L,
- Groopman JD. Absense of correlations among three pupative in vivo probes of human cytochrome P4503A activity in young healthy men.// Clin Pharmacol Ther. 1993- 54: 621−629.
- Kinirons MT, O’Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ and Wilkinson GR. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. // Clin. Pharm. Ther. 1999,66: 224−231.
- Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P, Breimer DD. Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. // Clin Pharmacol Ther.- 1986−40:21−28.
- Lennard M. S., Ramsey L. E., Silas J. H., Tucker G. Т., Woods H. F. // Protecting the poor metaboliser: clinical consequences of genetic polymorphism of drug oxidation. // Pharm. Int.- 1983, Vol.4 P.61−65-
- Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG CoA reductase inhibitors. Similarites and differences. // Clin. -Pharmacokinet /1997/ May- 32 (5): 403−25
- Levy RH. Metabolic drug interactions. //Clin. Pharmacol. Ther. 2000- 27: 133−145.
- Lewis D.F.V., Dickins M., Eddershaw P.J., Tarbit M.H., Goldfard P. S. Cytochrome P450 Substrate Specificities, Substrate structural Templates and Enzyme Active Site Geometries. // Drug metabolism and drug interactions. 1999- Vol. 15, 1: 1−51.
- Linder MW., Prough RA., Valdes R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. // Clinical Chemistry 1997- 43: 254 266.
- Liska De, AJ. The Detoxification Enzyme Systems. // Altern Med Rev. -1998- 3 (3): 187−198.
- Lu A.Y.H. Drug-Metabolism Research Challenges in the New Millennium. //J. Clin. Pharmacol. -1998- 12: 17−22.
- McGilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, Brodie MJ. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. // Gut 1986- 27: 190- 195.
- McKinnon RA, Burgess WM, Hall P, deLa M, Roberts-Thompson SJ, Gonzalez FJ and McManus ME. Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues. //Gut -1995- 36: 259−267.
- Mets B. Lidocaine extrastion by the in vivo and isolaned perfused pig liver.//J. Hepatol. 1994- 21 (6): 1067−1074.
- Meyer JM., Rodvord KA. Drug biotransformation by the cytochrome P450 enzyme system. // Infect Med. -1996- 13 (6): 452,459,463−464,523.
- Michalets EL. Update: clinically significant cytochrome P-450 drug interactions.//Pharmacotherapy 1998- 18: 84−112.
- Nakachi K, Imai K, Hayashi S, Watanabe J. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. // Cancer Res. -1991- 51: 5177−5180.
- Nebert D.W., Adesnik M., Coon M.J. et al. The P450 gene superfamily: recommended nomenclature. // DNA 1987, 6: 1−11.
- Nebert D.W., Nelson D.R. and Adesnik M. et al. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci.// DNA-1989, 8: 1−13.
- Nelson D.R. Cytochrome P450 and the individuality of Species. // Archives of Biochem. Biophys. 1999- 369, 1 issue: 1−10.
- Oellerich M, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.// Therapeutic Drug Monitoring. 1990- 12: 219−226.
- Oellerich M, Raude E, Burdelski M. et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. // J. Clin.Chem. Clin.Biochem. 1987- 25: 845−853.
- Oellerich M, Schtitz E, Polzien F, Ringe B, Armstrong VW, Hartmann H, et al. Influence of gender on the monoethylglycinexylidide test in normalsubjects and liver donors. // Ther Drug Monit. 1994- 16: 225−231.
- Opie LH. Calcium channel antagonists: Part VI: clinical pharmacokinetics of first and second-generation agents. // Cardiovasc. Drugs Ther. 1989- 3: 482−497.
- Pacifici GM, Eligi M and Giuliani L. (+) and (-) terbutaline are sulfated at a higher rate in human intestine than in liver.// Eur J Clin Pharmacol. 1993- 45: 483−487.
- Pacifici GM, Franchi M and Bencini F. Tissue distribution of drug metabolizing enzymes in human. // Xenobiotica -1988- 18: 849−856.
- Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE. First-pass metabolism of midazolam by the human intestine. // Clin Pharmacol Ther. 1996- 60:14.24.
- Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. // Clin Pharmacokinet. 1992- 23: 106−131.
- Pesola GR and Walle T. Stereoselective sulfate conjugation of isoproterenol in humans: Comparison of hepatic, intestinal and platelet activity.// Chirality-1993- 5: 602−609.
- Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. // Pharmacotherapy-1999- 19: 1378−1384.
- Poulsen HE, Loft S. The impact of genetic polymorphisms in risk assessment of drugs. // Arch Toxicol Suppl.- 1994- 16:211−212.
- Pursell P.N. MEGX production parallels changes in hepatic blood flow and oxygen delivery in lung injury managed with PEEP. // The Journal of Trauma. -1992 — (33) 3: 182−188.
- Raemsch K.D., Sommer J. Pharmacokinetics and metabolism of nifedipine.
- Supp II Hypertension Vol.5, No. 4:18−24.
- Rebbeck T. R., Jaffe J. M., Walker A. H, Wein A. J, Malkowicz S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. // J Nat Cancer Inst. -1998- 90: 1225−1229.
- Reitberg DP, Klarnet JP, Carlson JK, Schentag JJ. Effect of metronidazole on theophylline pharmacokinetics. // Clin Pharm. 1983- 2:441- 444.
- Rivory LP, Qin H, Clarke SJ, Eris J, Duggin G, Ray E, Trent RJ, Bishop JF. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance.// Eur J Clin Pharmacol. 2000- 56 (5): 395−398.
- Schroter J. Lidocaine metabolite formation: as an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. // Anaesthesia. 1995 (50) — 850−854.
- Scott EM, Wright RC. Variability of glutathione S-transferase of human erythrocytes. // Am. J. Hum. Genet.-1980- 32: 115−117.
- Schuetz EG, Yasuda K, Arimori K, Schuetz JD. Human MDR1 and mouse mdrla P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo (a)pyrene. // Arch. Biochem Biophys. -1998,350: 340−347.
- Shiffman M. Use of hepatic lidocaine metabolism to monitor parients with CLD. // Therapeutic Drug Monitoring. -1996- 18: 372−377.
- Sotaniemi E. CYP3A4 and CYP2D6 activites marked by metabolism of lidocaine and coumarin.// Am. J. Hum. Genet .-1997- 12: 190−196.
- Strange RC, Matharoo B, Faulder GC, Jones P, Cotton W, Elder JB,
- Deakin M. The human glutathione S -transferases: а сase-control study о f the incidence of the GST1 0 phenotype in patients with adenocarcinoma. // Carcinogenesis -1991- 12: 25−28.
- Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four flourometric substances. // Drug Metab Dispos.- 2000,28: 1440−1448.
- Sturgill MG., Lambert GH. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. // Clinical Chemistry. -1997- 43: 1512−1526.
- Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam, and ketoconazole in Caco-2 cells. // Eur. J. Pharm.-1998, 358: 289−294.
- The Pharmacological basis of therapeutics. 9-th ed./ Hardman JG., Googman A., Gilman L., Limbird E. С. 11−17.
- Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. // Ann Rev Pharmacol Toxicol. 1998, 38: 389 430.
- Timbrell JA, Wright JM, Baillie T A. Monoacetylhydrazine as a metabolite of isoniazid in man. // Clin. Pharm. Therap.-1977- 22: 602−609.
- Waxman DJ, Chen L, Hecht JE, Jounaidi Y Cytochrome P450- based cancer gene therapy: recent advances and future prospects. // Drug Metab Rev. 1999- 31, 503−522.
- Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. // Am. J. Hum. Genet.- 1980- 32: 651−662.
- Wildt, de SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450f^h ЗА: ontogeny and drug disposition.// Clin Pharmacokinet -1999- 37(6): 485 505.
- Wolf C. R., Smith G. Pharmacogenetics. // BMJ 2000- 320: 987−990.
- Woolf T.F. Handbook of drug metabolism. // BMJ- 1999- 153−169.
- Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).// Molecular Pharm. -1990, 38: 207−213.
- Wu С Y, В enet L Z, H ebert M F, G upta S K, R owland M, G omez D Y a nd Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine.// Clin Pharmacol Ther. -1995- 58:492−497.
- Yamazoe Y, Nagata K, Yoshinari K, Fujita K, Shiraga T, Iwasaki K. Sulfotransferase catalyzing sulfation of heterocyclic amines.// Cancer Lett. -1999 — 143 (2): 103−107.
- Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.// J Clin Pharmacol. 1999- 39: 1203−1211
- Zanetta SA, Cresteil S, Deroussent T, Pein A, Raymond F, Vernillet E, Risse ML, Boige V, Gouyette A, Vassal G. Metabolism of irinotecan (CPT-11)by CYP3A4 and CYP3A5 in humans. //Clin. Cancer Res. -2000, 6: 2012−2020.
- Zots R. Value of extended MEGX formation test and other dynamic liver function tests in liver transplant donors. // Transplantation. -1997- 63: 538.